Hudson Value Partners LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Hudson Value Partners LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,614 shares of the medical research company’s stock after acquiring an additional 1,356 shares during the period. Thermo Fisher Scientific makes up about 1.6% of Hudson Value Partners LLC’s holdings, making the stock its 23rd biggest position. Hudson Value Partners LLC’s holdings in Thermo Fisher Scientific were worth $5,148,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. U.S. Capital Wealth Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 5.6% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 1,779 shares of the medical research company’s stock valued at $721,000 after acquiring an additional 95 shares during the last quarter. Accurate Wealth Management LLC increased its position in shares of Thermo Fisher Scientific by 15.5% in the second quarter. Accurate Wealth Management LLC now owns 789 shares of the medical research company’s stock worth $338,000 after purchasing an additional 106 shares during the last quarter. Finally, Foster Victor Wealth Advisors LLC raised its stake in Thermo Fisher Scientific by 5.2% in the second quarter. Foster Victor Wealth Advisors LLC now owns 529 shares of the medical research company’s stock valued at $222,000 after purchasing an additional 26 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Frederick M. Lowery sold 6,913 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the completion of the sale, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,586,868.56. This represents a 32.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Lisa P. Britt sold 10,225 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the sale, the vice president directly owned 14,145 shares in the company, valued at $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 131,767 shares of company stock valued at $76,467,793. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $639.03 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The stock’s 50 day simple moving average is $589.96 and its 200 day simple moving average is $529.43. The firm has a market cap of $240.09 billion, a price-to-earnings ratio of 36.92, a PEG ratio of 4.19 and a beta of 0.91. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. During the same quarter in the prior year, the firm posted $5.28 earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Analysts Set New Price Targets

TMO has been the topic of several research reports. Evercore ISI restated an “outperform” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a research note on Sunday, December 7th. JPMorgan Chase & Co. increased their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. Finally, Argus increased their price target on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $625.47.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.